MDGL
Price
$327.10
Change
-$7.50 (-2.24%)
Updated
Apr 3 closing price
Capitalization
7.23B
39 days until earnings call
ZLAB
Price
$36.69
Change
+$0.26 (+0.71%)
Updated
Apr 3 closing price
Capitalization
4.01B
39 days until earnings call
Ad is loading...

MDGL vs ZLAB

Header iconMDGL vs ZLAB Comparison
Open Charts MDGL vs ZLABBanner chart's image
Madrigal Pharmaceuticals
Price$327.10
Change-$7.50 (-2.24%)
Volume$223.31K
Capitalization7.23B
Zai Lab
Price$36.69
Change+$0.26 (+0.71%)
Volume$1.22M
Capitalization4.01B
MDGL vs ZLAB Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. ZLAB commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and ZLAB is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (MDGL: $327.10 vs. ZLAB: $36.69)
Brand notoriety: MDGL and ZLAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 61% vs. ZLAB: 119%
Market capitalization -- MDGL: $7.23B vs. ZLAB: $4.01B
MDGL [@Biotechnology] is valued at $7.23B. ZLAB’s [@Biotechnology] market capitalization is $4.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileZLAB’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • ZLAB’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than ZLAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 3 TA indicator(s) are bullish while ZLAB’s TA Score has 3 bullish TA indicator(s).

  • MDGL’s TA Score: 3 bullish, 4 bearish.
  • ZLAB’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than ZLAB.

Price Growth

MDGL (@Biotechnology) experienced а -3.02% price change this week, while ZLAB (@Biotechnology) price change was +1.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

MDGL is expected to report earnings on May 13, 2025.

ZLAB is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.23B) has a higher market cap than ZLAB($4.01B). ZLAB YTD gains are higher at: 40.092 vs. MDGL (6.005). ZLAB has higher annual earnings (EBITDA): -242.99M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. ZLAB (780M). MDGL has less debt than ZLAB: MDGL (120M) vs ZLAB (153M). ZLAB has higher revenues than MDGL: ZLAB (399M) vs MDGL (180M).
MDGLZLABMDGL / ZLAB
Capitalization7.23B4.01B181%
EBITDA-450.12M-242.99M185%
Gain YTD6.00540.09215%
P/E RatioN/AN/A-
Revenue180M399M45%
Total Cash926M780M119%
Total Debt120M153M78%
FUNDAMENTALS RATINGS
MDGL vs ZLAB: Fundamental Ratings
MDGL
ZLAB
OUTLOOK RATING
1..100
7382
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
27100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
3936
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZLAB's Valuation (55) in the Biotechnology industry is in the same range as MDGL (70) in the Pharmaceuticals Other industry. This means that ZLAB’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is significantly better than the same rating for ZLAB (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than ZLAB’s over the last 12 months.

ZLAB's SMR Rating (96) in the Biotechnology industry is in the same range as MDGL (98) in the Pharmaceuticals Other industry. This means that ZLAB’s stock grew similarly to MDGL’s over the last 12 months.

ZLAB's Price Growth Rating (36) in the Biotechnology industry is in the same range as MDGL (39) in the Pharmaceuticals Other industry. This means that ZLAB’s stock grew similarly to MDGL’s over the last 12 months.

ZLAB's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that ZLAB’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLZLAB
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RWX24.770.26
+1.06%
SPDR® Dow Jones® International RelEstETF
TDTF24.200.22
+0.92%
FlexShares iBoxx 5Yr Target Dur TIPS ETF
FTSM59.900.05
+0.08%
First Trust Enhanced Short Maturity ETF
MIG21.34-0.01
-0.04%
VanEck IG Corporate ETF
PSMD28.08-0.80
-2.77%
Pacer Swan SOS Moderate (January) ETF

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-2.24%
KANT - MDGL
62%
Loosely correlated
-3.88%
ALXO - MDGL
56%
Loosely correlated
-10.48%
ZNTL - MDGL
51%
Loosely correlated
-7.55%
CGEM - MDGL
50%
Loosely correlated
-4.22%
TSVT - MDGL
50%
Loosely correlated
+0.20%
More

ZLAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ONC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ONC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
+0.71%
ONC - ZLAB
42%
Loosely correlated
-3.81%
MDGL - ZLAB
38%
Loosely correlated
-2.24%
GOSS - ZLAB
33%
Loosely correlated
-3.79%
AMRN - ZLAB
33%
Loosely correlated
-2.18%
ABOS - ZLAB
33%
Poorly correlated
-8.52%
More